Toddler’s Backyard Snakebite Bills Totaled More Than a Quarter Million Dollars
For snakebite victims, antivenom is critical — and costly. It took more than $200,000 worth of antivenom to save one toddler’s life after he was bitten by a rattlesnake.
The independent source for health policy research, polling, and news.
441 - 460 of 1,900 Results
For snakebite victims, antivenom is critical — and costly. It took more than $200,000 worth of antivenom to save one toddler’s life after he was bitten by a rattlesnake.
Nineteen states are seeking to stall a Biden administration rule that would allow recipients of the Deferred Action for Childhood Arrivals program to enroll in ACA coverage and qualify for subsidies. DACA provides work authorization and temporary deportation protection to people brought to the U.S. as children without immigration paperwork.
Experts disputed the claim by Republican vice presidential candidate JD Vance, noting that a range of other issues — from low reimbursement rates to declining patient use — combine to cause these facilities to shutter.
The United States has made almost no progress in closing racial health disparities despite promises, research shows. The government, some critics argue, is often the underlying culprit.
Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts. Georgia Republican Gov. Brian Kemp, though, vetoed a related bill that would have helped independent pharmacies, citing the unfunded cost of the move.
Health care hasn’t figured prominently on the campaign trail this fall. These voters wish it would.
Clinicians and researchers are searching for answers to whether an incidental finding on breast X-rays could improve the detection of cardiovascular disease risk among women.
Every year, Medicare officials encourage beneficiaries to shop around for their drug coverage. Few take the time. This year, it might be more important than ever.
This legislative cycle, Gov. Gavin Newsom signed bills affirming reproductive rights and mandating insurance coverage of in vitro fertilization, but the Democrat was reluctant to impose new regulations and frequently cited costs for vetoing bills.
The Affordable Care Act has not been a major issue in the 2024 campaign, but abortion and reproductive rights have been front and center. Those are just two of the dozens of health issues that could be profoundly affected by who is elected president and which party controls Congress in 2025. In this special live episode, Tamara Keith of NPR, Alice Miranda Ollstein of Politico, and Cynthia Cox and Ashley Kirzinger of KFF join Թϲ chief Washington correspondent Julie Rovner to discuss how health policy has affected the campaign and how the election results might affect health policy. Plus, the panel answers questions from the live audience.
Small-town doctors may not offer IUDs and hormonal implants because the devices require training to administer and are expensive to stock.
The Biden administration has taken significant steps to address a problem that burdens 100 million people in America, but gains would be jeopardized by a Trump win, advocates say.
As part of her presidential campaign, Vice President Kamala Harris has rolled out a plan for Medicare to provide in-home long-term care services. The proposal would fill a longtime need for families trying to simultaneously care for young children and older parents, but its enormous price tag makes it a promise unlikely to be fulfilled. Meanwhile, a growing number of Republican candidates up and down the ballot facing voter backlash over their support for abortion restrictions are trying to reinvent their positions. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico join Թϲ’ Julie Rovner to discuss these stories and more. Also this week, excerpts from a KFF lunch with “Shark Tank” panelist and generic drug discounter Mark Cuban, who has been consulting with the Harris campaign about health care issues.
An extra $99 fee on top of a copay for a checkup didn’t sit right with a listener. Turns out, state legislators across the country aren’t buying it either.
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
This year’s start date in most states is Nov. 1, and consumers may encounter new scams as well as important rule changes.
In red and blue states, state lawmakers from both parties are expanding protections for patients burdened by medical debt.
© 2026 KFF